Evaluation for the clinical significance of cancer-association in anti-SRP antibody-positive myopathy

Abstract

Background: Both anti-SRP and anti-HMGCR antibodies (Abs) are recognized as markers of necrotizing autoimmune myopathies. We recently identified that anti-HMGCR Ab was second most frequently detected in cancer-associated myositis (CAM) and that the synchronous occurrence of cancers and myopathies, advanced cancers and poor prognosis were frequently observed in HMGCR-CAM. Previous studies reported that cancers were detected in 5-17% of anti-SRP Ab+ myopathy, however, clinical features of SRP-CAM patients has not been well assessed and cancer-association in anti-SRP Ab+ myopathy remains controversial to date.